Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution